EMCURE - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.6
| Stock Code | EMCURE | Market Cap | 32,213 Cr. | Current Price | 1,691 ₹ | High / Low | 1,830 ₹ |
| Stock P/E | 48.5 | Book Value | 170 ₹ | Dividend Yield | 0.18 % | ROCE | 13.5 % |
| ROE | 11.6 % | Face Value | 10.0 ₹ | DMA 50 | 1,578 ₹ | DMA 200 | 1,453 ₹ |
| Chg in FII Hold | -0.24 % | Chg in DII Hold | 0.00 % | PAT Qtr | 282 Cr. | PAT Prev Qtr | 118 Cr. |
| RSI | 56.2 | MACD | 43.3 | Volume | 8,61,477 | Avg Vol 1Wk | 7,80,446 |
| Low price | 950 ₹ | High price | 1,830 ₹ | PEG Ratio | -3.58 | Debt to equity | 0.50 |
| 52w Index | 84.2 % | Qtr Profit Var | 462 % | EPS | 33.7 ₹ | Industry PE | 30.9 |
📊 EMCURE shows moderate fundamentals and is a fair candidate for long-term investment, but with caution. ROE (11.6%) and ROCE (13.5%) are decent but not very strong compared to peers. Debt-to-equity (0.50) is manageable but higher than ideal. The P/E ratio (48.5) is significantly above industry average (30.9), suggesting premium valuation. Dividend yield is low (0.18%), limiting income appeal. The PEG ratio (-3.58) indicates distorted valuation relative to growth, which is a concern. However, strong quarterly PAT growth (282 Cr vs 118 Cr) and EPS of ₹33.7 show improving profitability.
💡 Ideal Entry Price Zone: Accumulation is attractive around ₹1,550–₹1,600, near 50 DMA and 200 DMA support. Current price of ₹1,691 is slightly above ideal entry, making it better to wait for dips.
⏳ Exit Strategy / Holding Period: If already holding, investors may hold for 2–3 years to see if profitability sustains. Consider partial profit booking near ₹1,800–₹1,830 if valuations stretch. Long-term holding beyond 3 years requires improvement in ROE, ROCE, and reduction in valuation premium.
✅ Positive
- EPS of ₹33.7 reflects solid earnings power.
- PAT growth (₹282 Cr vs ₹118 Cr) shows strong operational performance.
- Stock trading above 50 DMA and 200 DMA, showing bullish momentum.
- MACD and RSI indicate healthy technical strength.
⚠️ Limitation
- P/E ratio (48.5) is much higher than industry average (30.9).
- PEG ratio (-3.58) indicates distorted valuation relative to growth.
- Dividend yield is very low (0.18%), limiting income potential.
- Debt-to-equity ratio (0.50) is higher than ideal for long-term stability.
📉 Company Negative News
- Decline in FII holdings (-0.24%), showing reduced foreign investor confidence.
- High valuation compared to industry peers may limit near-term upside.
📈 Company Positive News
- PAT surged significantly compared to previous quarter.
- Stable DII holdings, showing domestic institutional support.
- Strong EPS growth supports premium valuation.
🏭 Industry
- Industry PE (30.9) is lower than company PE, suggesting EMCURE trades at a premium.
- Pharmaceutical sector benefits from long-term demand growth and innovation.
🔎 Conclusion
EMCURE is a moderate long-term investment candidate with improving profitability but stretched valuations. Investors can accumulate near ₹1,550–₹1,600 and hold for 2–3 years. Partial profit booking near ₹1,800–₹1,830 is advisable unless fundamentals strengthen further. Long-term attractiveness depends on sustained earnings growth and improvement in efficiency metrics.